Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

被引：0

作者：

Lorusso, D. ^{[1
,2
]}

Xiang, Y. ^{[3
]}

Hasegawa, K. ^{[4
]}

Scambia, G. ^{[2
,5
]}

Leiva Galvez, M. H. ^{[6
]}

Elias, P. Ramos ^{[7
]}

Acevedo, A. ^{[8
]}

Bednarikova, M. ^{[9
,10
]}

Gomes, A. J. P. D. S. ^{[11
]}

Mejia, F. Contreras ^{[12
]}

Reiss, A. ^{[13
]}

Zagouri, F. ^{[14
]}

Lee, J-Y. ^{[15
]}

Saevets, V. ^{[16
]}

Ayhan, A. ^{[17
]}

Liu, P. ^{[18
]}

Yamada, K. U. ^{[18
]}

Puglisi, M. ^{[18
]}

Pignata, S. ^{[19
]}

Duska, L. ^{[20
]}

机构：

[1] Fdn Policlin Univ A Gemelli IRCCS, Gynaecol Oncol Unit, Rome, Italy

[2] Univ Cattolica Sacro Cuore, Rome, Italy

[3] Peking Union Med Coll Hosp, Natl Clin Res Ctr Obstetr & Gynecol Dis, Dept Obstet & Gynecol, Beijing, Peoples R China

[4] Saitama Med Univ, Gynecol Oncol Dept, Int Med Ctr, Saitama, Japan

[5] Fdn Policlin Univ A Gemelli IRCCS, Sci Directorate, Rome, Italy

[6] Inst Oncol & Radioterapia Clin Ricardo Palma, Med Oncol, Lima, Peru

[7] Edificio Integra Med Ctr, Integra Canc Inst, Guatemala City, Guatemala

[8] Oncocentro, Med Oncol, Vina Del Mar, Chile

[9] Univ Hosp Brno, Brno, Czech Republic

[10] Masaryk Univ, Fac Med, Brno, Czech Republic

[11] Liga Norte Riograndense Contra O Canc, Med Oncol & Med Oncol Res, Natal, Brazil

[12] Inst Nacl Cancerol, Clin Oncol, Bogota, Colombia

[13] Rambam Med Ctr, Gynecooncol Unit, Haifa, Israel

[14] Alexandra Gen Hosp, Clin Therapeut, Athens, Greece

[15] Yonsei Univ, Severance Hosp, Coll Med, Seoul, South Korea

[16] Chelyabinsk Reg Clin Ctr Oncol & Nucl Med, Dept Gynaecol, Chelyabinsk, Russia

[17] Baskent Univ, Turkish Soc Gynecol Oncol TRSGO, Ankara, Turkey

[18] Merck & Co Inc, Oncol, Rahway, NJ USA

[19] Ist Nazl Tumori IRCCS Fdn G Pascale, Dept Urol & Gynecol, Naples, Italy

[20] Univ Virginia, Obstet & Gynecol, Sch Med, Charlottesville, VA USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.771

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

709O

引用

页码：S544 / S544

页数：1

共 50 条

[1] Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Duska, Linda
Xiang, Yang
Hasegawa, Kosei
Scambia, Giovanni
Leiva, Manuel
Elias, Pier Anyelo
Acevedo, Alejandro
Vizkeleti, Julia
Juliana Gomes, Andrea
Contreras Mejia, Fernando
Reiss, Ari
Ayhan, Ali
Lee, Jung-Yun
Saevets, Valeriya
Zagouri, Flora
Li, Kan
Yamada, Karin
Toker, Sarper
Pignata, Sandro
Lorusso, Domenica
GYNECOLOGIC ONCOLOGY, 2024, 190 : S8 - S9
[2] Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: the randomized, double-blind, phase 3 ENGOT-Cx11/GOG-3047/KEYNOTE-A18 study
Lorusso, Domenica
Xiang, Yang
Hasegawa, Kosei
Scambia, Giovanni
Leiva, Manuel
Ramos-Elias, Pier
Acevedo, Alejandro
Vizkeleti, Julia
Gomes, Andrea
Mejia, Fernando Contreras
Reiss, Ari
Ayhan, Ali
Lee, Jung-Yun
Saevets, Valeriya
Zagouri, Flora
Li, Kan
Yamada, Karin
Toker, Sarper
Pignata, Sandro
Duska, Linda R.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A2 - A2
[3] Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, doubleblind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Lorusso, D.
Xiang, Y.
Hasegawa, K.
Scambia, G.
Galves, M. H. Leiva
Elias, P. Ramos
Acevedo, A.
Vizkeleti, J.
Gomes, A. J. P. D. S.
Mejia, F. Contreras
Reiss, A.
Ayhan, A.
Lee, J. Y.
Saevets, V.
Zagouri, F.
Li, K.
Yamada, K. Ussui
Toker, S.
Pignata, S.
Duska, L. R.
ANNALS OF ONCOLOGY, 2023, 34 : S1279 - S1280
[4] ENGOT-CX11/GOG 3047/KEYNOTE-A18: PHASE 3 RANDOMIZED STUDY OF PEMBROLIZUMAB plus CHEMORADIOTHERAPY FOR HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER
Lorusso, D.
Xiang, Y.
Colombo, N.
Coleman, R. L.
Randall, L. M.
Duska, L.
Hasegawa, K.
Nogueira-Rodrigues, A.
Cibula, D.
Mirza, M. R.
You, B.
Oaknin, A.
Christiaens, M.
Taskiran, C.
Sehouli, J.
Korach, J.
Marth, C.
Yamada, K.
Puglisi, M.
Pignata, S.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A19 - A20
[5] ENGOT-CX11/GOG 3047/KEYNOTE-A18: A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PEMBROLIZUMAB WITH CHEMORADIOTHERAPY IN PATIENTS WITH HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER
Lorusso, D.
Colombo, N.
Coleman, R.
Randall, L.
Duska, L.
Xiang, Y.
Hasegawa, K.
Nogueira-Rodrigues, A.
Cibula, D.
Mirza, M. Raza
You, B.
Oaknin, A.
Christiaens, M.
Taskiran, C.
Sehouli, J.
Korach, J.
Martin, C.
Keefe, S.
Puglisi, M.
Pignata, S.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A71 - A71
[6] Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial
Lorusso, Domenica
Xiang, Yang
Hasegawa, Kosei
Scambia, Giovanni
Leiva, Manuel
Ramos-Elias, Pier
Acevedo, Alejandro
Sukhin, Vladyslav
Cloven, Noelle
Gomes, Andrea J. Pereira de Santana
Mejia, Fernando Contreras
Reiss, Ari
Ayhan, Ali
Lee, Jung-Yun
Saevets, Valeriya
Zagouri, Flora
Gilbert, Lucy
Sehouli, Jalid
Tharavichitkul, Ekkasit
Lindemann, Kristina
Lazzari, Roberta
Chang, Chih-Long
Lampe, Rudolf
Zhu, Hong
Oaknin, Ana
Christiaens, Melissa
Polterauer, Stephan
Usami, Tomoka
Li, Kan
Yamada, Karin
Toker, Sarper
Keefe, Stephen M.
Pignata, Sandro
Duska, Linda R.
OBSTETRICAL & GYNECOLOGICAL SURVEY, 2024, 79 (09) : 523 - 524
[7] ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer
Lorusso, D.
Xiang, Y.
Colombo, N.
Coleman, R.
Randall, L.
Duska, L.
Hasegawa, K.
Nogueira-Rodrigues, A.
Cibula, D.
Mirza, M. R.
You, B.
Oaknin, A.
Christiaens, M.
Taskiran, C.
Sehouli, J.
Korach, J.
Marth, C.
Keefe, S.
Puglisi, M.
Pignata, S.
ANNALS OF ONCOLOGY, 2020, 31 : S1341 - S1342
[8] ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer.
Lorusso, Domenica
Colombo, Nicoletta
Coleman, Robert L.
Randall, Leslie M.
Duska, Linda R.
Xiang, Yang
Hasegawa, Kosei
Rodrigues, Angelica Nogueira
Cibula, David
Mirza, Mansoor Raza
You, Benoit
Oaknin, Ana
Christiaens, Melissa
Taskiran, Cagatay
Braicu, Elena Ioana
Korach, Jacob
Marth, Christian
Keefe, Stephen Michael
Puglisi, Martina
Pignata, Sandro
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Lorusso, Domenica
Xiang, Yang
Hasegawa, Kosei
Scambia, Giovanni
Leiva, Manuel
Ramos-Elias, Pier
Acevedo, Alejandro
Sukhin, Vladyslav
Cloven, Noelle
Gomes, Andrea J. Pereira de Santana
Mejia, Fernando Contreras
Reiss, Ari
Ayhan, Ali
Lee, Jung-Yun
Saevets, Valeriya
Zagouri, Flora
Gilbert, Lucy
Sehouli, Jalid
Tharavichitkul, Ekkasit
Lindemann, Kristina
Lazzari, Roberta
Chang, Chih-Long
Lampe, Rudolf
Zhu, Hong
Oaknin, Ana
Christiaens, Melissa
Polterauer, Stephan
Usami, Tomoka
Li, Kan
Yamada, Karin
Toker, Sarper
Keefe, Stephen M.
Pignata, Sandro
Duska, Linda R.
LANCET, 2024, 403 (10434): : 1341 - 1350
[10] Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Thomalla, Goetz
Bonekamp, Susanne
Fiehler, Jens
Bendszus, Martin
LANCET, 2024, 404 (10464): : 1730 - 1730

← 1 2 3 4 5 →